1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genscript Biotech Corporation

Genscript Biotech Corporation

1548.HK
Genscript Biotech CorporationHK flagHong Kong Stock Exchange
13.84
HKD
+0.64
- -
30.24BMarket Cap
Genscript Biotech Corporation
1548.HK
(Hong Kong Stock Exchange)

Recent

price

13.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.04
0.07
0.07
0.09
0.13
0.15
0.21
0.24
0.3
0.27
0.28
0.44
Revenue per Share
- -
0.01
0.02
0.02
0.01
-0.05
-0.11
-0.18
-0.11
-0.05
1.4
-0.25
Basic EPS, GAAP
- -
0.01
0.01
-0.01
0.13
-0.08
-0.15
-0.13
-0.15
-0.21
-0.03
0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.04
0.04
0.06
0.06
0.01
-0.1
-0.14
-0.25
-0.29
1.11
0.84
Book Value per Share
0.04
0.12
0.11
0.13
0.26
0.17
0.58
0.66
0.64
0.96
2.03
1.82
Tangible Book Value per Share
1,600
1,193
1,667
1,714
1,792
1,854
1,901
2,031
2,097
2,109
2,121
2,167
Basic Weighted Avg Shares
70
87
115
153
231
273
391
490
626
560
594
960
Sales/Revenue/Turnover
11.83
13.16
23.03
28.73
3.77
-45.14
-49.12
-75.33
-68.36
7.17
3.82
27.32
Operating Margin (%)
5
5
5
7
13
21
33
48
64
74
78
74
Depreciation Expense
6
18
26
26
21
-97
-205
-359
-227
-95
2,962
-533
Net Income, GAAP
21.2
23.82
18.38
29.9
8.55
- -
- -
- -
- -
3.56
- -
- -
Effective Tax Rate (%)
8.82
20.19
22.81
17.11
9.18
-35.45
-52.44
-73.19
-36.26
-17.03
498.22
-55.53
Profit Margin (%)
15
102
125
125
526
330
712
1,226
1,219
1,858
54
359
Working Capital
- -
- -
- -
- -
- -
5
8
148
305
351
74
55
LT Debt
62
149
184
228
493
372
1,133
1,388
1,363
2,044
4,323
3,965
Total Equity
- -
8.11
12.64
14.32
2.1
- -
- -
- -
- -
1.84
- -
- -
Return on Invested Capital (%)
- -
41.69
39.59
27.2
17.73
- -
- -
- -
- -
52.31
- -
- -
Return on Capital (%)
- -
41.7
42.21
30.97
20.27
-147
- -
- -
- -
- -
- -
-25.54
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
51.71%
34.78%
-8.3%
Free Cash Flow
-283.69%
-92.86%
-434.41%
Net Income, GAAP
-375.46%
-667.96%
-117.99%
Sales/Revenue/Turnover
28.81%
22.02%
61.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
560
2024
- -
- -
- -
- -
594
2025
- -
- -
- -
- -
960

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.05
2024
- -
- -
- -
- -
1.4
2025
- -
- -
- -
- -
-0.25

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Marvel Biosciences Corp. (MRVL.V)
Cara Therapeutics, Inc. (CARA)
Tesaro, Inc. (TSRO)
Modern Technology Corp. (MODC)
Mind Cure Health Inc. (MCUR.CN)
ToolGen Inc (199800.KS)
Business
Genscript Biotech Corporation (1548.HK), founded in 2002 and headquartered in Nanjing, China, with primary U.S. operations in Piscataway, New Jersey, operates as a leading global biotechnology company providing life science research products and services; it offers gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production and purification, antibody development and production including monoclonal antibodies via platforms like MonoRab and PrecisionAb, custom peptides with modifications such as fluorescent labels and biotinylation, CRISPR gene editing, next-generation sequencing services, molecular biology tools and reagents, life-science equipment and consumables, as well as preclinical drug development services encompassing in vitro and in vivo pharmacology, protein engineering, and cell therapy solutions; the company serves pharmaceutical, biotech, academic institutions, and researchers worldwide across North America, Europe including a Netherlands subsidiary, Asia-Pacific with a new Sydney hub, and other regions. Genscript Biotech organizes into key segments including the Life Science Group for research services and products, and ProBio for contract development and manufacturing organization (CDMO) activities in biologics and cell/gene therapies. In recent developments, ProBio opened a flagship U.S. plasmid and viral vector manufacturing facility in Hopewell, New Jersey in June 2025 to advance cell and gene therapy production; the company formed a strategic partnership with NSG Bio in April 2025 to drive biotechnology innovation, announced a collaboration with Bioelectronica in May 2025 for antibody development using single B-cell screening technology, expanded its partnership with Roche ongoing since 2011, earned an EcoVadis Silver Medal in July 2025 ranking in the top 15% globally for sustainability, released its 2024 ESG report in April 2025, achieved SBTi verification of carbon reduction goals in February 2025, and reported FY 2024 financial results in March 2025.

Company News

APIChatGPT

  • headlinesoftoday.com

    GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis